RT Journal Article
T1 IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response
A1 Leyva-Fernández, Laura
A1 Fernández Fernández, Óscar
A1 Fedetz, María
A1 Blanco, Eva
A1 Fernández Sánchez, Victoria Eugenia
A1 Oliver-Martos, Begoña
A1 León, Antonio
A1 Pinto-Medel, María-Jesús
A1 Mayorga Mayorga, Cristobalina
A1 Guerrero, Miguel
A1 Luque, Gloria
A1 Alcina, Antonio
A1 Matesanz, Fuencisla
K1 Esclerosis múltiple
AB We investigated the role of three polymorphisms in the IFNAR1 (SNPs 18417 and -408) and IFNAR2 (SNP 11876) genes in multiple sclerosis (MS) susceptibility and in the IFNbeta treatment response in a group of 147 patients and 210 controls undergoing interferon therapy during the last 2 years. Only the 18417 and the 11876 SNPs showed an association with disease susceptibility (p =0.001 and 0.035, respectively) although no differential genotype distribution were observed between interferon responders and non-responder MS patients. No alteration of the expression level of IFNAR-1 was observed with respect to the -408 genotypes or to interferon treatment response. These data suggest a role for the IFNAR pathway in susceptibility to MS.
PB Elsevier
YR 2005
FD 2005
LK https://hdl.handle.net/10630/33078
UL https://hdl.handle.net/10630/33078
LA eng
NO Leyva L, Fernández O, Fedetz M, Blanco E, Fernández VE, Oliver B, León A, Pinto-Medel MJ, Mayorga C, Guerrero M, Luque G, Alcina A, Matesanz F. IFNAR1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol. 2005 Jun;163(1-2):165-71. Epub 2005 Apr 22. PMID: 15885318.
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 12 abr 2026